Market Research Logo

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

Summary

Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared to other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure. Although only 4-8% of patients in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Australia) are diagnosed with unresectableStage III or Stage IV metastatic disease, a significant proportion of resectableStage III disease (42-48%) progresses to metastatic melanoma.

It is estimated that the value of the melanoma market in the US, five major European markets (5EU: France, Germany, Italy, Spain, and the UK), and Australia in 2016 was about $3.3B. This market is defined as sales of the major branded drugs commonly prescribed for melanoma patients across the 7MM. Among these sales, over 65% (over $2B) were generated in the US, with the 5EU representing the next largest region by sales with an estimated 28% (over $900M).

By the end of the forecast period in 2026, melanoma projects sales to rise to about $5.5B in the 7MM, at a modest Compound Annual Growth Rate (CAGR) of just over 5%. In particular, the US melanoma market is expected to grow most rapidly, increasing to over $3.5B (around 70% share) by 2026, at a modest CAGR of 5.8%. Sales in the other regions are expected to increase by the end of the forecast period at CAGRs of around 4% for the 5EU and Australia.

It is expected that the approval of 10 pipeline agents would happen over the forecast period; however, few of these are expected to have a major impact on the overall melanoma market. Of these pipeline agents, Incyte’s IDO inhibitor epacadostat represents the sales leader with peak-year sales of $383.4M in 2026.

The report PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026, provide overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Furthermore, this report provides the following -

  • Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: AB Science, Amgen, Array BioPharma, AVAX Technologies, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Merck & Co, Novartis

Scope
  • Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Modest Growth in the Melanoma Market Expected from 2016-2026
2.2 Despite Strong Competition, Bristol-Myers Squibb to Remain the Leader of the Checkpoint Immunotherapy and Overall Melanoma Market
2.3 High Unmet Need Remains for Efficacious Treatment Options in BRAF Wild-Type Patients
2.4 High Commercial Opportunity for Adjuvant Treatments that Improve Cure Rates in Early-Stage, Resectable Melanoma Patients
2.5 Innovative Immune Checkpoint Inhibitor Combinations Strive for Market Penetration Due to a Crowded Melanoma Market
2.6 Late-Stage Pipeline Agents to Have Limited Impact on the Future Melanoma Landscape
2.7 What Do the Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Melanoma Biomarkers
4.2 Clinical Staging
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Melanoma (2016-2026)
5.5.1 Diagnosed Incident Cases of Melanoma
5.5.2 Age-Specific Diagnosed Incident Cases of Melanoma
5.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma
5.5.4 Five-Year Diagnosed Prevalent Cases of Melanoma
5.5.5 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Guidelines, Leading Prescribed Drugs, and Clinical Practice
6.2.1 Localized Melanoma: Stage 0 to Stage IIc
6.2.2 Regional Melanoma: Stage IIIa to Stage IIIc
6.2.3 Advanced (Unresectable and Metastatic) Melanoma: Stage III and Stage IV
6.3 US
6.3.1 Screening and Diagnosis
6.3.2 Clinical Practices
6.4 France
6.4.1 Screening and Diagnosis
6.4.2 Clinical Practices
6.5 Germany
6.5.1 Screening and Diagnosis
6.5.2 Clinical Practices
6.6 Italy
6.6.1 Screening and Diagnosis
6.6.2 Clinical Practices
6.7 Spain
6.7.1 Screening and Diagnosis
6.7.2 Clinical Practices
6.8 UK
6.8.1 Screening and Diagnosis
6.8.2 Clinical Practices
6.9 Australia
6.9.1 Screening and Diagnosis
6.9.2 Clinical Practices
7 Competitive Assessment
7.1 Overview
7.2 Interferon-Based Adjuvant Therapies
7.2.1 Roferon-A (Interferon Alfa-2a)
7.2.2 Intron A (Interferon Alfa-2b)
7.2.3 Sylatron (Peginterferon Alfa-2b)
7.3 Immune Checkpoint Inhibitors
7.3.1 Yervoy (Ipilimumab)
7.3.2 Opdivo (Nivolumab)
7.3.3 Keytruda (Pembrolizumab)
7.4 BRAF and MEK Targeted Therapies
7.4.1 Zelboraf (Vemurafenib)
7.4.2 Cotellic (Cobimetinib)
7.4.3 Tafinlar (Dabrafenib)
7.4.4 Mekinist (Trametinib)
7.5 Oncolytic Viral Therapy
7.5.1 Imlygic (Talimogene Laherparepvec)
7.6 Other Therapeutic Classes
8 Unmet Need and Opportunity
8.1 Overview
8.2 Therapeutic Options for BRAF Wild-Type Patients
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Therapies for Non-responders to PD-1 Immunotherapy
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Neoadjuvant and Adjuvant Therapies for High-Risk Resectable Melanoma
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Effective Treatment for Brain Metastases
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 Predictive Markers for Therapeutic Response to Immunotherapies
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Immune Checkpoint Inhibitors
9.3.1 Epacadostat
9.3.2 Tecentriq (Atezolizumab)
9.3.3 PDR-001
9.4 Molecular Targeted Therapies
9.4.1 Encorafenib (LGX818)
9.4.2 Binimetinib (MEK162)
9.4.3 Masitinib (AB-1010)
9.5 Other Immune-Related Therapies
9.5.1 Seviprotimut-L
9.5.2 PV-10
9.5.3 M-Vax
9.5.4 Daromun (L19-IL2 + L19-TNF)
9.6 Promising Drugs in Early-Stage Development
9.6.1 Immunotherapies
9.6.2 Molecular Targeted Therapies
9.6.3 Oncolytic Viral Therapies, Adoptive T-cell Therapies, and Immunostimulants
9.7 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Bristol-Myers Squibb
10.3.2 Novartis
10.3.3 Merck & Co
10.3.4 Roche
10.3.5 Incyte
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers- US
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers -5EU
11.4 Australia
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers - Australia
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Forecasting Methodology
12.4.1 Diagnosed Melanoma Patients
12.4.2 Percent Drug-Treated Patients
12.4.3 Drugs Included in Each Therapeutic Class
12.4.4 Launch and Patent Expiry Dates
12.4.5 General Pricing Assumptions
12.4.6 Average Body Weight and Surface Area Across the 7MM
12.4.7 Individual Drug Assumptions
12.4.8 Pricing of Pipeline Agents
12.5 Primary Research - KOLs Interviewed for This Report
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analyst
12.7.2 Therapy Area Directors
12.7.3 Epidemiologist
12.7.4 Epidemiology Reviewers
12.7.5 Global Director of Therapy Analysis and Epidemiology
12.7.6 Global Head and EVP of Healthcare Operations and Strategy
12.8 About GlobalData
12.9 Contact Us
12.10 Disclaimer
1.1 List of Tables
Table 1: Melanoma: Key Metrics in Seven Major Pharmaceutical Markets
Table 2: Pathologic Stage Definitions for Melanoma
Table 3: The ABCED Rule of Melanoma Detection
Table 4: Prognosis of Melanoma
Table 5: Risk Factors for Melanoma
Table 6: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026
Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026
Table 8: Clinical Guidelines for Melanoma
Table 9: Most Prescribed Drugs for Melanoma in the Global Markets by Class, 2016
Table 10: Country Profile - US
Table 11: Country Profile - France
Table 12: Country Profile - Germany
Table 13: Country Profile - Italy
Table 14: Country Profile - Spain
Table 15: Country Profile - UK
Table 16: Country Profile - Australia
Table 17: Leading Treatments for Melanoma, 2016
Table 18: Product Profile - Roferon-A
Table 19: Efficacy of Roferon-A
Table 20: Safety of Roferon-A
Table 21: Roferon-A SWOT Analysis, 2016
Table 22: Product Profile - Intron A
Table 23: Efficacy of Intron A from the Phase III E1684 Trial
Table 24: Safety of Intron A (E1684, E1690, and E1694)
Table 25: Intron A SWOT Analysis, 2015
Table 26: Product Profile - Sylatron
Table 27: Efficacy of Sylatron from the EORTC 18991 Trial
Table 28: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon
Table 29: Safety of Sylatron from the EORTC 18991 Trial
Table 30: Sylatron SWOT Analysis, 2015
Table 31: Product Profile - Yervoy
Table 32: Yervoy Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 33: Yervoy Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 34: Yervoy Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 35: Efficacy of Yervoy from the Phase III CA184-002 Trial
Table 36: Comparison of Higher Dose Yervoy and DTIC from the CA184-024 Trial
Table 37: Network Meta-analysis of Yervoy in the Advanced Setting
Table 38: Efficacy Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial
Table 39: Efficacy of Yervoy in the Adjuvant Melanoma Setting from the CA184-029 Trial
Table 40: Safety of Yervoy at 3mg/kg in the Advanced Melanoma Setting from the CA184-002 trial
Table 41: Safety Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial
Table 42: Safety of Yervoy in the Adjuvant Setting from the CA184-029 Trial
Table 43: Yervoy SWOT Analysis, 2017
Table 44: Product Profile - Opdivo
Table 45: Opdivo’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 46: Opdivo’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 47: Opdivo’s Key Regulatory Milestones in the Australian Melanoma Market
Table 48: Efficacy of Opdivo in 1L BRAF-WT Advanced Melanoma from the CheckMate 066 Trial
Table 49: Efficacy of Opdivo + Yervoy from the CheckMate 067 Trial
Table 50: Safety Data from the CheckMate 037 Trial
Table 51: Safety Data from the CheckMate 066 Trial
Table 52: Safety Data from the CheckMate 067 Trial
Table 53: Opdivo SWOT Analysis, 2017
Table 54: Product Profile - Keytruda
Table 55: Keytruda Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 56: Keytruda Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 57: Keytruda Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 58: Survival Data from the Phase Ib KEYNOTE-001 Trial
Table 59: Efficacy of Keytruda from the KEYNOTE-002 Trial
Table 60: Efficacy of Keytruda from the KEYNOTE-006 Trial
Table 61: Efficacy of Keytruda in Combinations in the 1L Setting
Table 62: Safety Data from the KEYNOTE-001 Trial
Table 63: Safety of Keytruda from the KEYNOTE-002 Trial
Table 64: Safety Data from the KEYNOTE-006 Trial
Table 65: Safety of Keytruda in the 1L Setting from 2016 ASCO Annual Meeting
Table 66: Keytruda SWOT Analysis, 2017
Table 67: Product Profile - Zelboraf
Table 68: Zelboraf’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 69: Zelboraf’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 70: Zelboraf’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 71: Efficacy of Zelboraf
Table 72: Safety of Zelboraf
Table 73: Zelboraf SWOT Analysis, 2017
Table 74: Product Profile - Cotellic
Table 75: Cotellic’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 76: Cotellic’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 77: Cotellic’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 78: Efficacy of Cotellic in BRAF V600 Mutation-Positive Advanced Melanoma from the coBRIM Trial
Table 79: Safety Data of Cotellic from the coBRIM Trial
Table 80: Cotellic SWOT Analysis, 2017
Table 81: Product Profile - Tafinlar
Table 82: Tafinlar’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 83: Tafinlar’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 84: Tafinlar’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 85: Efficacy of Tafinlar Monotherapy from the BREAK-3 Trial
Table 86: Safety of Tafinlar
Table 87: Tafinlar SWOT Analysis, 2017
Table 88: Product Profile - Mekinist
Table 89: Mekinist’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 90: Mekinist’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 91: Mekinist’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 92: Efficacy of Mekinist from the Phase III METRIC Trial
Table 93: Efficacy Results of Tafinlar + Mekinist from the Phase II NCT01072175 Trial
Table 94: Efficacy Results of the COMBI-d Trial
Table 95: Efficacy Results of Tafinlar + Mekinist from the COMBI-v Trial
Table 96: Safety of Mekinist from the Phase III METRIC Trial
Table 97: Safety Results of the COMBI-d Trial
Table 98: Safety Results of the COMBI-v Trial
Table 99: Mekinist SWOT Analysis, 2017
Table 100: Product Profile - Imlygic
Table 101: Imlygic’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 102: Imlygic’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 103: Imlygic’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 104: Efficacy of Imlygic from the Phase III OPTiM Trial
Table 105: Exploratory Subgroup Analyses from the Phase III OPTiM Trial
Table 106: Safety of Imlygic from the Phase III OPTiM Trial
Table 107: Imlygic SWOT Analysis, 2017
Table 108: Summary of Minor Therapeutic Classes, 2017
Table 109: Product Profile - Epacadostat
Table 110: Efficacy of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial
Table 111: Safety Data of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial
Table 112: Epacadostat SWOT Analysis, 2017
Table 113: Product Profile - Tecentriq
Table 114: Tecentriq SWOT Analysis, 2017
Table 115: Product Profile - PDR-001
Table 116: PDR-001 SWOT Analysis, 2017
Table 117: Product Profile - Encorafenib
Table 118: Efficacy of Encorafenib from the Phase III COLUMBUS Trial
Table 119: Safety of Encorafenib Regimens from the Phase III COLUMBUS Trial
Table 120: Encorafenib SWOT Analysis, 2017
Table 121: Product Profile - Binimetinib
Table 122: Efficacy of Binimetinib from the Phase III NEMO Trial
Table 123: Safety of Binimetinib from the Phase III NEMO Trial
Table 124: Binimetinib SWOT Analysis, 2017
Table 125: Product Profile - Masitinib
Table 126: Masitinib SWOT Analysis, 2017
Table 127: Product Profile - Seviprotimut-L
Table 128: Efficacy of Seviprotimut-L from the Phase II POL 89-38 Trial
Table 129: Seviprotimut-L SWOT Analysis, 2017
Table 130: Product Profile - PV-10
Table 131: Efficacy of PV-10 from the PV-10-MM-02 Trial
Table 132: Safety of PV-10
Table 133: PV-10 SWOT Analysis, 2017
Table 134: Product Profile - M-Vax
Table 135: Efficacy of M-Vax from the Phase I/II NCT00257465 Trial
Table 136: M-Vax SWOT Analysis, 2017
Table 137: Product Profile - Daromun (L19-IL2 + L19-TNF)
Table 138: Efficacy of Daromun from the Phase II NCT02076633 Trial
Table 139: Daromun SWOT Analysis, 2017
Table 140: Clinical Settings of Early-Stage Immunotherapies
Table 141: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors
Table 142: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway
Table 143: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints
Table 144: Clinical Settings of Early-Stage Oncolytic Viral, Adoptive T-cell and Immunostimulants
Table 145: Drugs in Development, 2017
Table 146: Key Companies in the Melanoma Market in the 7MM, 2017
Table 147: BMS’ Melanoma Portfolio Assessment, 2017
Table 148: Novartis’ Melanoma Portfolio Assessment, 2017
Table 149: Merck & Co’s Melanoma Portfolio Assessment, 2017
Table 150: Roche’s Melanoma Portfolio Assessment, 2017
Table 151: Incyte’s Melanoma Portfolio Assessment, 2017
Table 152: Melanoma Market in the 7MM - Drivers, 2016-2026
Table 153: Melanoma Market in the 7MM - Barriers, 2016
Table 154: Key Events Impacting Sales for Melanoma in the US, 2016-2026
Table 155: Melanoma Market in the US - Drivers and Barriers, 2016-2026
Table 156: Key Events Impacting Sales for Melanoma in the 5EU, 2016-2026
Table 157: Melanoma Market in the 5EU - Drivers and Barriers, 2016-2026
Table 158: Melanoma Market in the 5EU - Country-Specific Drivers, 2016-2026
Table 159: Melanoma Market in the 5EU - Country-Specific Barriers, 2016-2026
Table 160: Key Events Impacting Sales for Melanoma in Australia, 2016-2026
Table 161: Melanoma Market in Australia - Drivers and Barriers, 2016-2026
Table 162: Key Launch Dates
Table 163: Key Patent Expiries
Table 164 Average Body Weight and Surface Area Across the 7MM
Table 165: High-Prescribing Physicians Surveyed by Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Melanoma in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in Melanoma During the Forecast Period, 2016-2026
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Melanoma, 2016-2026
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2006-2026
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2006-2026
Figure 6: 7MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of Melanoma, 2016
Figure 7: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of Melanoma, 2016
Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, 2016
Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Melanoma, Men and Women, 2016
Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Melanoma, Ages ≥18 Years, 2016
Figure 11: 7MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Men and Women, Ages ≥18 Years, 2016
Figure 12: Treatment Flowchart for Localized Melanoma
Figure 13: Treatment Flowchart for Regional Melanoma
Figure 14: Treatment Flowchart for Recurrent Melanoma
Figure 15: Treatment Flowchart for Advanced Melanoma
Figure 16: Yervoy’s Development in Melanoma
Figure 17: Opdivo’s Recent and Future Development in Melanoma
Figure 18: Keytruda’s Development in Melanoma
Figure 19: Zelboraf’s Development in Melanoma
Figure 20: Cotellic’s Recent and Future Development in Melanoma
Figure 21: Tafinlar’s Development in Melanoma
Figure 22: Mekinist’s Development in Melanoma
Figure 23: Imlygic’s Development in Melanoma
Figure 24: Unmet Need and Opportunity in Melanoma, 2016
Figure 25: Overview of the Development Pipeline in Melanoma
Figure 26: Melanoma - Phase III Pipeline, 2017
Figure 27: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2016-2026
Figure 28: Clinical and Commercial Positioning of Epacadostat
Figure 29: Clinical and Commercial Positioning of Tecentriq
Figure 30: Clinical and Commercial Positioning of PDR-001
Figure 31: Clinical and Commercial Positioning of Encorafenib
Figure 32: Clinical and Commercial Positioning of Binimetinib
Figure 33: Clinical and Commercial Positioning of Masitinib
Figure 34: Clinical and Commercial Positioning of Seviprotimut-L
Figure 35: Clinical and Commercial Positioning of PV-10
Figure 36: Clinical and Commercial Positioning of M-Vax
Figure 37: Clinical and Commercial Positioning of Daromun
Figure 38: Global Sales of Branded Products for Melanoma by Company, 2016-2026
Figure 39: Company Portfolio Gap Analysis in Melanoma, 2016-2026
Figure 40: Global (7MM) Sales Forecast by Country for Melanoma in 2016 and 2026
Figure 41: Sales Forecast by Class for Melanoma in the US in 2016 and 2026
Figure 42: Sales Forecast by Class for Melanoma in the 5EU in 2016 and 2026
Figure 43: Sales Forecast by Class for Melanoma in Australia in 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report